Wednesday, 26 August 2026European Markets

MEDISTIM Stock Bullish Momentum With A 9.13% Jump Today

Loading stream...

(VIANEWS) - The Market ended the session with MEDISTIM (MEDI.OL) jumping 9.13% to kr239.00 on Wednesday while Oslo Børs Benchmark Index_GI jumped 0.13% to kr1,242.54.

MEDISTIM's last close was kr219.00, 33.64% below its 52-week high of kr330.00.

About MEDISTIM

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, MEDISTIM has a trailing twelve months EPS of kr5.31.

PE Ratio

MEDISTIM has a trailing twelve months price to earnings ratio of 45.01. Meaning, the purchaser of the share is investing kr45.01 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 31.12%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Apr 28, 2022, the estimated forward annual dividend rate is 3.75 and the estimated forward annual dividend yield is 1.7%.

More news about MEDISTIM (MEDI.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com